Razi Cov Pars

From Wikipedia, the free encyclopedia

Razi Cov Pars
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration
Intramuscular, Intranasal
Legal status
Legal status
  • Full list of Razi Cov Pars authorizations

Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute.[1][2][3]

It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.[4][5] It received emergency use authorization in Iran on 31 October 2021.[6][7]

Medical uses[]

It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).[3]

Pharmacology[]

Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.[2]

Manufacturing[]

It's planned to produce one million doses of the vaccine each month as of September 2021.[4]

Up to 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.[8]

History[]

Clinical trials[]

Clinical trials of Razi Cov Pars
Phase Registration number Start Number of participants Age of participants Ref
Total Vaccine Placebo
I IRCT20201214049709N1 21 January 2021 133 30 (5 µg/200µL)

30 (10 µg/200µL)

30 (20 µg/200µL)

30 (placebo)

13 (sentinel)

18-50 years [2]
II IRCT20201214049709N2 13 April 2021 500 18-70 years [3]
III IRCT20201214049709N3 29 August 2021 41,128 20,564 0 (placebo)

20,564 (Sinopharm BIBP vaccine)

18+ years [5]

Authorizations[]

Raz Cov Pars received emergency use authorization in Iran on 31 October 2021.[6][7]

See also[]

References[]

  1. ^ a b Mehdi, Syed Zafar (7 February 2021). "Iran unveils second homegrown COVID-19 vaccine". Anadolu Agency. Retrieved 22 April 2021.
  2. ^ a b c "Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. Retrieved 21 March 2021.
  3. ^ a b c "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. Retrieved 22 April 2021.
  4. ^ a b "COVID-19 vaccine Razi Cov Pars starts third clinical trial phase". Tehran Times. 27 August 2021. Retrieved 30 August 2021.
  5. ^ a b "IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial". en.irct.ir. Retrieved 30 August 2021.
  6. ^ a b "مجوز مصرف اضطراری داوطلبانه واکسن کووپارس صبح امروز صادر شد". ایسنا (in Persian). 31 October 2021. Retrieved 27 November 2021.
  7. ^ a b "Two homegrown vaccines receive emergency use license". Tehran Times. 1 November 2021. Retrieved 27 November 2021.
  8. ^ "۵ میلیون دز واکسن رازی به وزارت بهداشت تحویل داده شد". ایسنا (in Persian). 25 November 2021. Retrieved 27 November 2021.
Retrieved from ""